Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
about
Sphingolipids as Regulators of the Phagocytic Response to Fungal InfectionsCapsule independent uptake of the fungal pathogen Cryptococcus neoformans into brain microvascular endothelial cellsImproved survival of mice deficient in secretory immunoglobulin M following systemic infection with Cryptococcus neoformansCharacterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.Microevolution of a standard strain of Cryptococcus neoformans resulting in differences in virulence and other phenotypes.MP1 encodes an abundant and highly antigenic cell wall mannoprotein in the pathogenic fungus Penicillium marneffei.Isotype switching increases efficacy of antibody protection against Cryptococcus neoformans infection in micePhase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis.Characterization of AFMP1: a novel target for serodiagnosis of aspergillosis.The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibodyBoth Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.A comparison between intratracheal and inhalation delivery of Aspergillus fumigatus conidia in the development of fungal allergic asthma in C57BL/6 mice.Antibody action after phagocytosis promotes Cryptococcus neoformans and Cryptococcus gattii macrophage exocytosis with biofilm-like microcolony formation.CD4+ T cells mediate the protective effect of the recombinant Asp f3-based anti-aspergillosis vaccine.Roles for inositol-phosphoryl ceramide synthase 1 (IPC1) in pathogenesis of C. neoformans.Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.Role of sphingosine-1-phosphate (S1P) and S1P receptor 2 in the phagocytosis of Cryptococcus neoformans by alveolar macrophagesVaccines for invasive fungal infectionsQuantitative analysis of phagocytosis and killing of Cryptococcus neoformans by human peripheral blood mononuclear cells by flow cytometry.Cryptococcus neoformans melanin and virulence: mechanism of actionVariable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.Antibody immunity and invasive fungal infectionsPeroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages.Opsonization of Cryptococcus neoformans by human anticryptococcal glucuronoxylomannan antibodiesPeptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses.Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.Variable Region Identical IgA and IgE to Cryptococcus neoformans Capsular Polysaccharide Manifest Specificity Differences.IL-23 dampens the allergic response to Cryptococcus neoformans through IL-17-independent and -dependent mechanisms.T-Cell-independent humoral immunity is sufficient for protection against fatal intracellular ehrlichia infectionVaccine and immunotherapeutic approaches for the prevention of cryptococcosis: lessons learned from animal models.Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.Targeted gene disruption reveals an adhesin indispensable for pathogenicity of Blastomyces dermatitidis.Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy.Antibody-mediated modulation of Cryptococcus neoformans infection is dependent on distinct Fc receptor functions and IgG subclassesMolecular characterization of the early B cell response to pulmonary Cryptococcus neoformans infection.In vitro evaluation, biodistribution and scintigraphic imaging in mice of radiolabeled anthrax toxinsFc gamma receptor 3A polymorphism and risk for HIV-associated cryptococcal disease
P2860
Q26774635-F91BC143-927A-4390-AD9F-5E06FB933888Q28730545-B3DF71A8-6321-4308-9B1D-2E5D1F79F2EEQ33557968-A38CD503-31E1-4BA8-9DF7-585A06F27489Q33693515-FA0C2113-A2D4-47A7-91C3-6A9F7AA24A27Q33747538-608E755C-4BAA-40E8-814D-BC8925BF0579Q33751318-9B5CE658-659F-4F95-8E07-D9620C09CC2FQ33751509-44966BAB-7BAF-42D3-B771-29261CEB2C1AQ33857658-90EB68B5-A3B2-4120-88A6-C55A3EA84FBBQ33973840-BE9B3799-FB43-4234-953E-DC32F1180CE5Q33991158-76F314AB-CB01-4C17-8136-CAE952654F1CQ34001243-32773522-8C28-4F1D-AE03-17BA5831FEF5Q34001769-0382EF02-F063-4878-9C95-B67757E2A4B2Q34009446-3E769CC4-1216-4DF3-B3A4-67DEE073477EQ34644855-8AC26335-8F20-4583-8D5B-523707777DA7Q34961134-0925F4E7-32EF-426D-AD9D-B9C16C2C1CCEQ35075750-2A622178-3EE9-4062-83EE-C7BCB631D039Q35076570-20BF6CCF-63C8-4B12-89AC-535A904DDB9EQ35115708-612EEEE9-89DA-4BB0-A710-E4798104ACB5Q35118828-7FBFA68B-92A0-40E7-A153-DD30CD4393F2Q35161720-86A13EC9-A15B-4CAE-9FBE-4588F9810766Q35225136-3D33872F-7CCB-4EC1-8E28-EC608F2DF174Q35431176-00D3B679-A8A4-4C34-A9FE-0857CF9186B7Q35434901-E4CF425E-BC54-4B57-9B7A-76ED37201790Q35447692-FA76FAD2-4E0A-4275-A609-EAD93789DD38Q35511088-9DAC8887-43D9-401F-B72A-E64C3F0E7888Q35514947-9BAF65D3-B00A-4952-B4A9-427E9CBED9B9Q35544888-13CD1E37-BA40-46E6-BC9E-CE268F808B55Q35559940-AD6EF298-1816-4EB1-AF68-AD616A2ABFCEQ35567548-E442FEC2-2B35-4795-9C4F-301920008C54Q35583106-BDCE6E5E-BAB4-4DB9-B367-E46D0A7B0694Q35952109-6F16657B-FB0B-4EA8-9845-B77EC4B6BC19Q36097265-EFBBCDF6-17FC-4884-BDDF-E1FC7697CD94Q36192774-1DB1DA76-32AF-4EA1-8EBC-000E9602A487Q36366474-3817F0B8-6CC0-42EC-879A-335F2ED0131AQ36368074-5EBE79D8-01DD-4DEC-B1FE-835643BB28CDQ36376827-DF551C16-2C13-4660-A16E-16AF1EA5BBC7Q36400281-91DFEBF3-3AD7-4030-9CFB-D1ED14D300A9Q36456615-9820BD80-6D4C-4F54-9031-B0B5C14CD4D6Q37037248-EE665F56-9A4D-4D68-8B7B-352FB6438720Q37140093-AFFCAAC2-A120-4049-BDA5-AF40BA04C866
P2860
Antibodies to Cryptococcus neoformans glucuronoxylomannan enhance antifungal activity of murine macrophages
description
1995 nî lūn-bûn
@nan
1995 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
name
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@ast
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@en
type
label
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@ast
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@en
prefLabel
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@ast
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@en
P2093
P2860
P1476
Antibodies to Cryptococcus neo ...... activity of murine macrophages
@en
P2093
A Casadevall
S Mukherjee
P2860
P304
P407
P577
1995-02-01T00:00:00Z